Henri Deda

Henri Deda studied molecular Biotechnology at TU Dresden. At Lipotype, he developed a communication approach driven by providing access to expert knowledge to everyone.

Posts by henri.deda

Prof. Anne-Claude Gavin accepts 1st prize of LEA

The laureate of the world’s first Lipidomics Excellence Award, Prof. Dr. Anne-Claude Gavin from the University of Geneva , uses the analysis technology of Dresden based Lipotype GmbH for the next breakthrough in her lipid transfer research. The biochemist draws the world’s first molecular “map of lipid highways”, she is tracing the ways of lipid transfer between the membranes of body cells.

read more ➔

First large-scale study of the genetics of human plasma lipid species

Understanding the genetics of lipid species offers information beyond that provided by routine lipid screening, and can help improve risk prediction and treatment. In the first large-scale study, novel lipid-associated genetic variants were identified, some of which were linked with risk for cardiovascular disease, such as heart attacks and strokes. Lipotype provided the technology to measure these lipids – Lipotype Shotgun Lipidomics.

read more ➔


Dermal drug development for SLS associated ichthyosis

Aldeyra Therapeutics

Download Customer Reference

Sjögren-Larsson Syndrome (SLS) is a rare inborn error of aldehyde metabolism characterized by severe skin thickening (ichthyosis), retinal disease, and neurological dysfunction. As of today, no therapy that addresses SLS has been approved. Aldeyra Therapeutics has conducted a Phase 2 randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermal reproxalap for the treatment of ichthyosis associated with SLS. The results of the trial demonstrated clinically meaningful and statistically significant improvements of SLS skin symptoms of patients after only eight weeks of treatment. A multi-center Phase 3 clinical trial is ongoing.

Lipotype Shotgun Skin Lipidomics provided Aldeyra Therapeutics with lipid analysis of skin samples for identification of relevant lipid biomarkers in the Phase 2 clinical trial. Results of the skin lipidomics analysis delivered evidence for a correlation between clinical effects and those skin lipid biomarkers. Consistent with the clinical activity of reproxalap, significant dermal biomarker changes were noted in reproxalap-treated patients but not vehicle-treated patients. Cholesterol, which is significantly elevated in the skin of SLS patients, was reduced in reproxalap-treated patients more than in vehicle-treated patients.

Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated and metabolic diseases. Aldeyra’s lead product candidate, reproxalap (formerly called NS2), is a small molecule RASP (Reactive Aldehyde Species) inhibitor in Phase 3 clinical development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. With its focus on a carefully selected range of diseases, Aldeyra Therapeutics is devoted to improving lives through outstanding innovation.

Aldeyra therapeutics announces positive results from a randomized, double-blind, vehicle-controlled clinical trial of topical dermatologic nS2 in patients with Sjögren-Larsson syndrome – Aldeyra Therapeutics, 2016

read more ➔